Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP - Top-Institutions - MDSpire

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP

  • By

  • Feifei Wei

  • Yoshiro Nakahara

  • Junya Isobe

  • Yuka Igarashi

  • Haruhiro Saito

  • Shuji Murakami

  • Tetsuro Kondo

  • Hidetomo Himuro

  • Taku Kouro

  • Tomoya Matsui

  • Satoshi Wada

  • Takuya Tsunoda

  • Kiyoshi Yoshimura

  • Tetsuro Sasada

  • May 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #2

    Kanagawa Cancer Center
    Kanagawa Cancer Center

    Kanagawa, Japan

    Key Differentiators

    • Oncology

  • #3

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology

  • #5

    Gustave Roussy
    Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

Original Source(s)

Gut microbiome functional pathways outperform taxonomic profiles in predicting immune checkpoint inhibitor response in non-small cell lung cancer: an interpretable machine learning approach with SHAP

  • by Feifei Wei, Yoshiro Nakahara, Junya Isobe, Yuka Igarashi, Haruhiro Saito, Shuji Murakami, Tetsuro Kondo, Hidetomo Himuro, Taku Kouro, Tomoya Matsui, Satoshi Wada, Takuya Tsunoda, Kiyoshi Yoshimura, Tetsuro Sasada

  • May 15, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...